Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Its only approved oncology asset is idelalisib, marketed as Zydelig, which is a second line therapy with boxed warning in three indications: Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
IGF-1 LR3 has an arginine instead of a glutamic acid at the third position in its amino acid sequence and an additional 13 amino acids at its N-terminus
RealThiol (RT) Detection Probe provides ratiometric fluorescent readout for quantification of GSH in live mammalian cells
A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis
US$ 22.91
US$ 25.45
US$ 27.61
US$ 23.26
US$ 24.07
